Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine for Kidney Protection in Neonates With HIE
NCT05295784Phase 1Withdrawn
- Sponsor
- University of Arkansas
- Start
- May 2024
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of caffeine in acute kidney injury (AKI) (3 arms), sponsored by University of Arkansas. Primary endpoints: Clearance of caffeine at 1 week, Volume of distribution of caffeine at 1 week and 4 more. Planned start May 2024; status: withdrawn.
02
Drugs
caffeine
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05295784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295784.